Our Update on COVID-19

Para leer esto en español, haga click aqui.

Updated December 18, 2020

At Horizon, we are closely monitoring the COVID-19 pandemic and its effect on our communities. For the safety of our patients, healthcare professionals and our employees, we will continue to provide virtual assistance to physicians, patients and partners, as well as in-person, field-based support where state and local government guidelines allow. Regardless of where we are working, all of our patient and physician support services continue to be available and we remain fully committed to all of our communities during this unprecedented time.

Our Patients and Our Medicines

  • As always, our priority is ensuring patients have access to our medicines.
  • On Dec. 17, Horizon announced that it expects a short-term disruption in TEPEZZA® (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed. For more information, please read our statement.
  • At this time, we expect no further impact on the supply of our other medicines. We continue to closely monitor  our supply chain and will provide updates as necessary.
  • All of our patient services and financial support programs will continue to be available without interruption.
  • Patients currently prescribed a Horizon medicine who have a question should speak to their healthcare professional. In addition, if you are a patient who has a question specifically for Horizon, please contact our patient support team (the following link includes pertinent support team information for each of Horizon’s medicines): https://www.horizontherapeutics.com/patients/patient-support.

Our Research

  • The health and safety of patients enrolled or who may enroll in one of our clinical trials, as well as the investigators and staff administering the trials are paramount.
  • Our trials are currently ongoing and patients who have any questions should reach out directly to their treating physician.

Our Commitment

At Horizon, we believe it’s our responsibility to step up in times of crisis. To date, we have provided more than $3.7 million to COVID-19 relief efforts.

On March 26, we announced a $1.5 million donation to COVID-19 response efforts in Illinois and other impacted communities where our employees live and work.  We’ve provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund, as well as $500,000 to other organizations in need of critical services and supplies, including ALONE Ireland, the Lake County Crisis Relief Fund, the Chicago Community COVID-19 Response Fund, the Silicon Valley Community COVID-19 Coronavirus Regional Response Fund and the Greater Washington Community Foundation COVID-19 Emergency Response Fund. Read our full press release here.

On November 30, we announced an additional $1.2 million donation to U.S. and international organizations to support COVID-19 relief, including: The Chicago Community Trust, The Lake County Community Foundation, Silicon Valley Community Foundation, Greater Washington Community Foundation, Americares, ALONE, Family Carers Ireland, Enable Ireland and Toronto Foundation. Throughout 2020, Horizon has also provided more than $1 million to advocacy organizations to support COVID-19 relief initiatives for people living with rare and rheumatic diseases. This includes educational resources, emergency financial relief and internet connectivity to facilitate continued care via telehealth. Read our full press release here.

Contact Us

For medical information requests (healthcare professionals only), please call 1-866-479-6742 (option 1) or email medicalinformation@horizontherapeutics.com.

To report an adverse event or side effect, please call 1-866-479-6742 (option 1) or visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For all other inquiries, please call 1-866-479-6742 (option 3) or email customerservice@horizontherapeutics.com.